Schwarz and Mylan settle omeprazole dispute
Schwarz' Kremers Urban Development Company will pay Mylan and its development partner, Spain-based Esteve Quimica, $50 mil. under June 25 agreement to settle lawsuits related to generic omeprazole (1"The Pink Sheet" Aug. 11, 2003, p. 11). Mylan will receive $37.5 mil and Esteve Quimica will receive $12.5 mil...
You may also be interested in...
Mylan's decision to launch the second generic version of AstraZeneca's Prilosec (omeprazole) could inject a new level of price competition into the proton pump inhibitor category
Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials
Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.
Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker